Clinical trial
Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year
NCT02534363 is registered in ClinicalTrials.gov with Fundación Marques de Valdecilla as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: a Randomized Comparison of Aripiprazole, Quetiapine and Ziprasidone Over 1 Year
- Lead sponsor
- Fundación Marques de Valdecilla
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 31, 2005
- Completion date
- January 31, 2013
- Enrollment
- 136 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.